Pretomanid is remaining examined as Portion of a mixture program which include moxifloxacin and PZA for the treatment of equally drug-prone and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, accepted via the US FDA for treatment of multidrug-resistant tubercul